Gregory H Reaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory H Reaman has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Brigitte C. Widemann
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland
1 shared publication Catherine E Cottrell
Nationwide Children’s Hospital , Columbus, OH
1 shared publication- Diana L. Thomas
Department of Pathology, The Ohio State University, Columbus, OH, USA
1 shared publication - Douglas R. Lowy
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
1 shared publication - Douglas S. Hawkins
Seattle Children’s Hospital, University of Washington , Seattle, WA
1 shared publication - Elaine R. Mardis
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, USA
1 shared publication
Latest Publications
- 6 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 199-204
Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults
The Molecular Characterization Initiative (MCI), a key effort of the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children’s Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents, and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. Deidentified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI’s development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.
- 6 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 199-204
Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults
The Molecular Characterization Initiative (MCI), a key effort of the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children’s Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents, and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. Deidentified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI’s development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.